Who is Eduardo Clark?
Eduardo Clark serves as the Subsecretary of Sectoral Integration and Coordination of Health Services at Mexico’s Secretariat of Health. His role involves overseeing the integration of health services and coordinating medical attention across the country.
Key Developments in Mexico’s Drug Procurement
During a morning press conference with President Claudia Sheinbaum, Eduardo Clark announced that Mexico is expediting its large-scale drug purchase process for the 2027-2028 period. The goal is to finalize this procurement by May and early June.
Proactive Approach to Avoid Supply Shortages
Clark emphasized that the early initiation of this consolidated purchase process aims to prevent any potential shortages in hospitals, clinics, and health centers nationwide. This proactive planning includes anticipating the required medications, especially for diabetes treatment, for the next two years.
Incorporating Newer and Generic Drugs
The upcoming megacompra will include newer pharmaceuticals and those of new generations, along with a significant volume of generics. Clark highlighted that they are transitioning to more consolidated generic purchases based on doctors’ needs, as outlined in national medical care protocols.
Diabetes Medication Focus
Clark specifically mentioned a substantial shift in insulin treatments, replacing older options with glargine insulin, a new-generation basal insulin now available as a generic in larger quantities since its patent has expired.
Moreover, the portfolio will modernize, enhancing control over various diabetes medications. These include DPP4 inhibitors (sitagliptin and linagliptin) and SGLT2 inhibitors (dapagliflozin and empagliflozin), both of which are losing patent protection and demonstrating better outcomes compared to other medications.
Impact on Public Institutions and Patients
This strategic drug procurement ensures that public institutions like IMSS, ISSSTE, IMSS Bienestar, Pemex health services, and national health services have access to the recommended medications. This consistency benefits patients by ensuring they receive the same treatments prescribed by their doctors.
Current Status and Future Plans
Clark confirmed that they have secured fully guaranteed contracts to ensure medication supply for patients. Currently, approximately 200 million pieces are distributed monthly across hospitals, health centers, and clinics.
A significant portion of these medications targets diabetes and hypertension, as these conditions account for the largest number of beneficiaries within Mexico’s healthcare system.
Supply Stability Improvement
Clark noted that medication supply stabilized considerably in the second half of 2025, and this stability has continued into early 2026.
Key Questions and Answers
- Who is Eduardo Clark? Eduardo Clark is the Subsecretary of Sectoral Integration and Coordination of Health Services at Mexico’s Secretariat of Health.
- What is the purpose of Mexico’s early drug procurement? The goal is to avoid potential supply shortages in hospitals and health centers by securing medications needed for 2027-2028.
- Which medications are being prioritized? The procurement focuses on newer drugs, new-generation pharmaceuticals, and a significant volume of generics, with special attention to diabetes medications.
- How will this impact public institutions and patients? Public health institutions and patients will have consistent access to recommended medications, ensuring better control of conditions like diabetes and hypertension.
- What is the current status of drug procurement in Mexico? Mexico has secured guaranteed contracts to ensure medication supply for patients, distributing around 200 million pieces monthly.
- How has the stability of medication supply evolved? Supply stabilized significantly in the second half of 2025 and has maintained this stability into early 2026.
